Integra LifeSciences (IART) announced enrollment of the first patient in the Acclarent AERA Pediatric Registry, a prospective, multi-center observational registry evaluating the real-world use of the AERA Eustachian Tube Balloon Dilation System in children.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IART:
- Integra Lifesciences Amends Credit Agreement for Stability
- Integra Lifesciences Approves Equity Plan Amendment
- Integra LifeSciences price target lowered to $25 from $35 at Citizens JMP
- Integra LifeSciences price target lowered to $15 from $19 at Truist
- Integra LifeSciences price target lowered to $13 from $25 at Wells Fargo